GLP-1 agonists linked to lower mortality in serious mental illness
A retrospective target trial emulation using the TriNetX electronic health record network compared adults initiating GLP-1 receptor agonists versus SGLT2 inhibitors, with propensity-matched cohorts including over 195,000 pairs with serious mental illness (bipolar disorder, major depressive disorder, or schizophrenia). The study reported lower 4-year and 1-year all-cause mortality and reduced major adverse cardiovascular events with GLP-1 RA initiation compared to SGLT2 inhibitor initiation, with the mortality association persisting across sensitivity analyses and SMI subgroups. The authors state that prospective randomized trials are warranted.
Most relevant for: Adults with bipolar disorder, major depressive disorder, or schizophrenia, particularly those with comorbid type 2 diabetes being considered for GLP-1 receptor agonist or SGLT2 inhibitor therapy.
Read the original at JAMA PsychiatrySummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More psychiatry updates
- Caring Letters Not Linked to Lower Suicide Mortality in VeteransOct 14, 2026
- US benzodiazepine dispensing fell 26.7% from 2013 to 2024Sep 30, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 5 mg per 1 mL, Delivers: 10 mL, Oral Elixir, PAI, Sep 23, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 5 mg per 10 mL, Delivers: 10 mL, Oral Elixir, PAI,Sep 23, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 10 mg per 2 mL, Delivers: 10 mL, Oral Elixir, PAI,Sep 23, 2026